Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 47

References for PMC Articles for PubMed (Select 19409036)

1.

High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy.

Zhang Y, Pastan I.

Clin Cancer Res. 2008 Dec 15;14(24):7981-6. doi: 10.1158/1078-0432.CCR-08-0324. Review.

2.

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.

Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, Adams GP.

Br J Cancer. 2008 Nov 4;99(9):1415-25. doi: 10.1038/sj.bjc.6604700. Epub 2008 Oct 7.

3.

Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.

Deyev SM, Lebedenko EN.

Bioessays. 2008 Sep;30(9):904-18. doi: 10.1002/bies.20805.

PMID:
18693269
4.

Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids.

Ackerman ME, Pawlowski D, Wittrup KD.

Mol Cancer Ther. 2008 Jul;7(7):2233-40. doi: 10.1158/1535-7163.MCT-08-0067.

5.

Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Thurber GM, Schmidt MM, Wittrup KD.

Adv Drug Deliv Rev. 2008 Sep;60(12):1421-34. doi: 10.1016/j.addr.2008.04.012. Epub 2008 Apr 24. Review.

6.

Antibody engineering principles and applications.

Loo L, Robinson MK, Adams GP.

Cancer J. 2008 May-Jun;14(3):149-53. doi: 10.1097/PPO.0b013e318173a5d5. Review.

PMID:
18536554
7.

Quantitative spatiotemporal analysis of antibody fragment diffusion and endocytic consumption in tumor spheroids.

Thurber GM, Wittrup KD.

Cancer Res. 2008 May 1;68(9):3334-41. doi: 10.1158/0008-5472.CAN-07-3018.

8.

Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability.

Schmidt MM, Thurber GM, Wittrup KD.

Cancer Immunol Immunother. 2008 Dec;57(12):1879-90. doi: 10.1007/s00262-008-0518-1. Epub 2008 Apr 12.

9.

Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.

Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI.

Clin Cancer Res. 2008 Apr 1;14(7):2171-9. doi: 10.1158/1078-0432.CCR-07-4465. Erratum in: Clin Cancer Res. 2008 May 1;14(9):2893.

10.

Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.

Tang Y, Lou J, Alpaugh RK, Robinson MK, Marks JD, Weiner LM.

J Immunol. 2007 Sep 1;179(5):2815-23.

11.

Novel antibodies as anticancer agents.

Zafir-Lavie I, Michaeli Y, Reiter Y.

Oncogene. 2007 May 28;26(25):3714-33. Review.

PMID:
17530025
12.

Theoretic criteria for antibody penetration into solid tumors and micrometastases.

Thurber GM, Zajic SC, Wittrup KD.

J Nucl Med. 2007 Jun;48(6):995-9. Epub 2007 May 15.

13.
14.

PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting.

Kubetzko S, Balic E, Waibel R, Zangemeister-Wittke U, Plückthun A.

J Biol Chem. 2006 Nov 17;281(46):35186-201. Epub 2006 Sep 8.

15.

Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.

Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW.

Cancer Res. 2006 Aug 1;66(15):7630-8.

16.

Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.

Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF 3rd, Houston LL, Huston JS, Weiner LM.

Clin Cancer Res. 2006 Mar 1;12(5):1599-605.

17.

Fully human therapeutic monoclonal antibodies.

Weiner LM.

J Immunother. 2006 Jan-Feb;29(1):1-9. Review.

PMID:
16365595
18.

Monoclonal antibody therapy of cancer.

Adams GP, Weiner LM.

Nat Biotechnol. 2005 Sep;23(9):1147-57. Review.

PMID:
16151408
19.

Engineered antibody fragments and the rise of single domains.

Holliger P, Hudson PJ.

Nat Biotechnol. 2005 Sep;23(9):1126-36. Review.

PMID:
16151406
20.

Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.

Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP.

Cancer Res. 2005 Feb 15;65(4):1471-8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk